Matching articles for "female sexual dysfunction"
Issue 1577 · July 29, 2019
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder

The FDA has approved bremelanotide ( Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):114-6
The FDA has approved bremelanotide ( Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin (Addyi) , which was approved in 2015, was the first.
Issue 1555 · September 10, 2018
Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia

The FDA has approved an estradiol softgel vaginal insert ( Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is…

Med Lett Drugs Ther. 2018 Sep 10; 60(1555):147-8
The FDA has approved an estradiol softgel vaginal insert ( Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is the second estradiol vaginal insert to be approved in the US; Vagifem , an intravaginal tablet formulation, was the first. Vagifem and Imvexxy are both available in inserts containing 10 mcg of estradiol; Imvexxy is also available in a 4-mcg strength.
Issue 1529 · September 11, 2017
Prasterone (Intrarosa) for Dyspareunia

The FDA has approved the steroid prasterone ( Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called…

Med Lett Drugs Ther. 2017 Sep 11; 59(1529):149-50
The FDA has approved the steroid prasterone ( Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.
Issue 1481 · November 9, 2015 Free
Addendum: Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder

When our article on flibanserin (Addyi) was published (Med Lett Drugs Ther 2015; 57:133) , the drug had not yet been marketed. Flibanserin became available on October 17, 2015 at a cost of $800 for a 30-day…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):156
When our article on flibanserin (Addyi) was published (Med Lett Drugs Ther 2015; 57:133) , the drug had not yet been marketed. Flibanserin became available on October 17, 2015 at a cost of $800 for a 30-day supply.
Issue 1478 · September 28, 2015
Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder

The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or psychiatric…

Med Lett Drugs Ther. 2015 Sep 28; 57(1478):133-5
The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or psychiatric condition, the effects of another drug, or relationship difficulties. Flibanserin is the first drug to be approved for treatment of HSDD. It is not approved for use in men or postmenopausal women. Previous FDA reviews of flibanserin in 2010 and 2013 did not result in approval.
Issue 1353 · December 13, 2010
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):100-2
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Issue 1259 · April 23, 2007
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.

Med Lett Drugs Ther. 2007 Apr 23; 49(1259):33-5
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.